JP2018519366A5 - - Google Patents

Download PDF

Info

Publication number
JP2018519366A5
JP2018519366A5 JP2018518786A JP2018518786A JP2018519366A5 JP 2018519366 A5 JP2018519366 A5 JP 2018519366A5 JP 2018518786 A JP2018518786 A JP 2018518786A JP 2018518786 A JP2018518786 A JP 2018518786A JP 2018519366 A5 JP2018519366 A5 JP 2018519366A5
Authority
JP
Japan
Prior art keywords
muscular atrophy
drug
condition causing
physical condition
fgf19 polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018518786A
Other languages
English (en)
Japanese (ja)
Other versions
JP6761929B2 (ja
JP2018519366A (ja
Filing date
Publication date
Priority claimed from EP15305990.2A external-priority patent/EP3108893A1/en
Application filed filed Critical
Publication of JP2018519366A publication Critical patent/JP2018519366A/ja
Publication of JP2018519366A5 publication Critical patent/JP2018519366A5/ja
Application granted granted Critical
Publication of JP6761929B2 publication Critical patent/JP6761929B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018518786A 2015-06-25 2016-06-24 Ｆｇｆ１９の新規な治療用途 Active JP6761929B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305990.2 2015-06-25
EP15305990.2A EP3108893A1 (en) 2015-06-25 2015-06-25 Novel therapeutic use of fgf19
PCT/EP2016/064671 WO2016207354A1 (en) 2015-06-25 2016-06-24 Novel therapeutic use of fgf19

Publications (3)

Publication Number Publication Date
JP2018519366A JP2018519366A (ja) 2018-07-19
JP2018519366A5 true JP2018519366A5 (2) 2019-08-22
JP6761929B2 JP6761929B2 (ja) 2020-09-30

Family

ID=53498933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018518786A Active JP6761929B2 (ja) 2015-06-25 2016-06-24 Ｆｇｆ１９の新規な治療用途

Country Status (5)

Country Link
US (1) US10695403B2 (2)
EP (2) EP3108893A1 (2)
JP (1) JP6761929B2 (2)
CA (1) CA2997652A1 (2)
WO (1) WO2016207354A1 (2)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
KR102729404B1 (ko) * 2016-11-04 2024-11-14 칠드런즈 호스피탈 메디칼 센터 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
JP2020100591A (ja) * 2018-12-21 2020-07-02 味の素株式会社 筋質向上剤
CN112057606B (zh) * 2020-09-14 2023-09-19 上海市儿童医院 Fgf19在治疗和/或预防脓毒症诱发的器官损伤的药物中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126852A1 (en) * 1997-11-25 2004-07-01 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
EP1032668B1 (en) * 1997-11-25 2008-05-28 Genentech, Inc. Fibroblast growth factor-19
WO2007100722A2 (en) * 2006-02-28 2007-09-07 Trustees Of Boston University Methods to identify factors associated with muscle growth and uses thereof
MX368790B (es) * 2009-10-15 2019-10-16 Genentech Inc Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
WO2013006486A2 (en) * 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases

Similar Documents

Publication Publication Date Title
JP2018519366A5 (2)
JP2017532343A5 (2)
JP2012041342A5 (2)
JP2011225596A5 (2)
JP2015518818A5 (2)
JP2015517488A5 (2)
JP2013542919A5 (2)
FI3721882T3 (fi) Aineenvaihduntahäiriöiden hoito hevoseläimissä
JP2005537234A5 (2)
HRP20201353T1 (hr) Agonisti glukagonskog receptora
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
NZ603200A (en) Peptides and their use
HRP20140616T1 (hr) Peptidni analog oksintomodulina
JP2016509011A5 (2)
JP2014530220A5 (2)
NZ611878A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
WO2015105981A3 (en) Nutritional composition comprising hmb for increasing or maintaining lean body mass in subjects having reduced leucine to hmb conversion efficiency or undergoing diabetic treatment
JP2009544585A5 (2)
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
MX2023010328A (es) Composiciones de medicamentos a base de peptido de colageno y metodos y dispositivos para su produccion y uso.
JP2013510169A5 (2)
RU2018125622A (ru) Способ применения карримицина против резистетности инфекции, спровоцированной микобактерией туберкулеза
JP2020533302A5 (2)
EA200600782A1 (ru) Терапевтические применения вариантов хемокинов
JP2009500045A5 (2)